Christopher J Langmead

List of Publications by Year
in descending order

86 papers	4,726 citations	126907 33 h-index	110387 64 g-index
91 all docs	91 docs citations	91 times ranked	5090 citing authors

#	Article	IF	Citations
1	Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Molecular Psychiatry, 2022, 27, 88-94.	7.9	15
2	Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors. Molecular Pharmacology, 2022, 101, 246-256.	2.3	7
3	Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities. ACS Pharmacology and Translational Science, 2022, 5, 183-188.	4.9	10
4	Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Translational Psychiatry, 2022, 12, 147.	4.8	29
5	M₁ muscarinic receptor activation decreases alcohol consumption via a reduction in consummatory behavior. Pharmacology Research and Perspectives, 2022, 10, e00907.	2.4	7
6	Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Frontiers in Pharmacology, 2021, 12, 628060.	3.5	5
7	Muscarinic M₄ and M₅ receptors in the ventral subiculum differentially modulate alcohol seeking versus consumption in male alcoholâ€preferring rats. British Journal of Pharmacology, 2021, 178, 3730-3746.	5.4	9
8	Identification of a Novel Allosteric Site at the M5 Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2021, 12, 3112-3123.	3.5	6
9	Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor. Biochemical and Biophysical Research Communications, 2021, 578, 84-90.	2.1	14
10	From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimerâ€™s disease. Cell, 2021, 184, 5886-5901.e22.	28.9	44
11	Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms. BMJ Open Diabetes Research and Care, 2021, 9, e002285.	2.8	6
12	Negative allosteric modulators of the human calciumâ€sensing receptor bind to overlapping and distinct sites within the 7â€transmembrane domain. British Journal of Pharmacology, 2020, 177, 1917-1930.	5.4	12
13	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Molecular Cell, 2020, 80, 485-500.e7.	9.7	111
14	Structure-based development of a subtype-selective orexin 1 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18059-18067.	7.1	33
15	Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. ACS Pharmacology and Translational Science, 2020, 3, 1042-1062.	4.9	6
16	Preface. Advances in Pharmacology, 2020, 88, xiii-xvii.	2.0	0
17	Î²-Arrestin-2-Dependent Mechanism of GPR52 Signaling in Frontal Cortical Neurons. ACS Chemical Neuroscience, 2020, 11, 2077-2084.	3.5	7
18	Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. Biological Psychiatry, 2020, 88, 898-909.	1.3	24

#	Article	IF	Citations
19	In the Loop: Extrastriatal Regulation of Spiny Projection Neurons by GPR52. ACS Chemical Neuroscience, 2020, 11, 2066-2076.	3.5	5
20	New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery. ACS Pharmacology and Translational Science, 2020, 3, 88-106.	4.9	80
21	Crystal structure of the M ₅ muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26001-26007.	7.1	48
22	The importance of sex differences in pharmacology research. British Journal of Pharmacology, 2019, 176, 4087-4089.	5.4	13
23	Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. Neuropharmacology, 2019, 144, 244-255.	4.1	22
24	Discovery and Optimization of Potent and CNS Penetrant M₅-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. ACS Chemical Neuroscience, 2018, 9, 1572-1581.	3.5	13
25	Structureâ€“Activity Relationships of Pan-GÎ±_{q/11} Coupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. ACS Chemical Neuroscience, 2018, 9, 1818-1828.	3.5	7
26	Muscarinic M5 receptors modulate ethanol seeking in rats. Neuropsychopharmacology, 2018, 43, 1510-1517.	5.4	33
27	Bitopic Binding Mode of an M₁ Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Molecular Pharmacology, 2018, 93, 645-656.	2.3	25
28	Divergent effects of strontium and calciumâ€sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity. British Journal of Pharmacology, 2018, 175, 4095-4108.	5.4	29
29	G Proteinâ€“Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. Pharmacological Reviews, 2018, 70, 39-67.	16.0	88
30	Molecular pharmacology of GPCRs. British Journal of Pharmacology, 2018, 175, 4005-4008.	5.4	5
31	Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research. PLoS ONE, 2018, 13, e0197177.	2.5	29
32	GPR52 is a key regulator of corticostriatal signalling and function. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-100.	0.0	0
33	GPCR allostery and bias in modern pharmacology: Structural, pharmacological and clinical implications. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, CL-23.	0.0	0
34	Isoform-Specific Biased Agonism of Histamine H₃Receptor Agonists. Molecular Pharmacology, 2017, 91, 87-99.	2.3	21
35	High throughput, quantitative analysis of human osteoclast differentiation and activity. Analytical Biochemistry, 2017, 519, 51-56.	2.4	7
36	Molecular Mechanisms of Action of M₅ Muscarinic Acetylcholine Receptor Allosteric Modulators. Molecular Pharmacology, 2016, 90, 427-436.	2.3	24

#	Article	IF	Citations
37	Positive Allosteric Modulation of the Muscarinic M₁Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 354-365.	2.5	21
38	Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants. PLoS ONE, 2016, 11, e0146846.	2.5	42
39	Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm, 2015, 6, 947-955.	3.4	15
40	Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists. Molecular Pharmacology, 2015, 88, 779-790.	2.3	17
41	Monoclonal anti-Î²1-adrenergic receptor antibodies activate G protein signaling in the absence of Î²-arrestin recruitment. MAbs, 2014, 6, 246-261.	5.2	31
42	Functional and structural perspectives on allosteric modulation of GPCRs. Current Opinion in Cell Biology, 2014, 27, 94-101.	5.4	32
43	Binding kinetics differentiates functional antagonism of orexinâ€2 receptor ligands. British Journal of Pharmacology, 2014, 171, 351-363.	5.4	55
44	From orphans to orexins: an arousing fifteen years. British Journal of Pharmacology, 2014, 171, 281-282.	5.4	1
45	International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands. Pharmacological Reviews, 2014, 66, 918-947.	16.0	189
46	Supraâ€physiological efficacy at <scp>GPCRs</scp>: superstition or super agonists?. British Journal of Pharmacology, 2013, 169, 353-356.	5.4	26
47	Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy. Molecular Pharmacology, 2013, 83, 949-958.	2.3	69
48	Discovery of 1,2,4-Triazine Derivatives as Adenosine A_{2A} Antagonists using Structure Based Drug Design. Journal of Medicinal Chemistry, 2012, 55, 1898-1903.	6.4	296
49	Identification of Novel Adenosine A_{2A} Receptor Antagonists by Virtual Screening. Journal of Medicinal Chemistry, 2012, 55, 1904-1909.	6.4	131
50	Ligand properties and behaviours in an allosteric age. Trends in Pharmacological Sciences, 2012, 33, 621-622.	8.7	6
51	The Use of GPCR Structures in Drug Design. Advances in Pharmacology, 2011, 62, 1-36.	2.0	38
52	Progress in Structure Based Drug Design for G Protein-Coupled Receptors. Journal of Medicinal Chemistry, 2011, 54, 4283-4311.	6.4	203
53	The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology, 2011, 60, 36-44.	4.1	148
54	The muscarinic M4 receptor is the functionally predominant subtype in rat and mouse striatum as demonstrated using [35S] GTPÎ³S binding. European Journal of Pharmacology, 2011, 652, 1-6.	3.5	10

#	Article	IF	Citations
55	Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature, 2011, 474, 521-525.	27.8	793
56	Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia. Molecular Pharmacology, 2011, 79, 874-885.	2.3	54
57	Determining Allosteric Modulator Mechanism of Action: Integration of Radioligand Binding and Functional Assay Data. Methods in Molecular Biology, 2011, 746, 195-209.	0.9	17
58	In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. European Journal of Pharmacology, 2010, 627, 106-114.	3.5	9
59	2â€² Biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3545-3549.	2.2	18
60	2â€² Biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3540-3544.	2.2	17
61	Matching models to data: a receptor pharmacologist's guide. British Journal of Pharmacology, 2010, 161, 1276-1290.	5.4	30
62	Performance of Mouse Neural Stem Cells as a Screening Reagent. Journal of Biomolecular Screening, 2010, 15, 159-168.	2.6	3
63	Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M₁Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2010, 78, 94-104.	2.3	61
64	Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M₁ mAChR Agonists. ACS Medicinal Chemistry Letters, 2010, 1, 244-248.	2.8	50
65	N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor. Neuropharmacology, 2010, 58, 1206-1214.	4.1	24
66	Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M₁ Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2009, 75, 331-341.	2.3	50
67	Contrasting Effects of Allosteric and Orthosteric Agonists on M₁Muscarinic Acetylcholine Receptor Internalization and Down-regulation. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 1086-1095.	2.5	33
68	Growth Hormone Secretagogues and Growth Hormone Releasing Peptides Act As Orthosteric Super-Agonists but Not Allosteric Regulators for Activation of the G Protein Gî±_{o1}by the Ghrelin Receptor. Molecular Pharmacology, 2009, 76, 802-811.	2.3	35
69	Evaluation of expression and function of the H+/myo-inositol transporter HMIT. BMC Cell Biology, 2009, 10, 54.	3.0	43
70	Characterization of a CNS penetrant, selective M₁muscarinic receptor agonist, 77â€ŁHâ€2âˆ1. British Journal of Pharmacology, 2008, 154, 1104-1115.	5.4	118
71	Muscarinic acetylcholine receptors as CNS drug targets. , 2008, 117, 232-243.		369
72	G Protein Coupling and Signaling Pathway Activation by M1 Muscarinic Acetylcholine Receptor Orthosteric and Allosteric Agonists. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 365-374.	2.5	52

#	Article	IF	Citations
73	Screening for Positive Allosteric Modulators: Assessment of Modulator Concentration-Response Curves as a Screening Paradigm. Journal of Biomolecular Screening, 2007, 12, 668-676.	2.6	7
74	Roof and Floor of the Muscarinic Binding Pocket: Variations in the Binding Modes of Orthosteric Ligands. Molecular Pharmacology, 2007, 72, 1484-1496.	2.3	40
75	Structure-Function Studies of Allosteric Agonism at M2Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2007, 72, 463-476.	2.3	105
76	Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist. Molecular Pharmacology, 2006, 69, 236-246.	2.3	101
77	SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2â€²methyl-4â€²-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl m 50, 984-990.	4.1	6
78	Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends in Pharmacological Sciences, 2006, 27, 475-481.	8.7	112
79	SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue. European Journal of Pharmacology, 2006, 536, 54-61.	3.5	15
80	Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. European Journal of Pharmacology, 2005, 510, 49-57.	3.5	106
81	Neurochemical Changes in LPA1 Receptor Deficient Mice â€“ A Putative Model of Schizophrenia. Neurochemical Research, 2005, 30, 371-377.	3.3	60
82	Characterisation of the binding of [3 H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. British Journal of Pharmacology, 2004, 141, 340-346.	5.4	129
83	Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neuroscience Letters, 2004, 366, 241-244.	2.1	54
84	The effect of SB-269970, a 5-HT7 receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. British Journal of Pharmacology, 2001, 132, 1574-1580.	5.4	37
85	Characterization of the binding of [125 I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor. British Journal of Pharmacology, 2000, 131, 683-688.	5.4	52
86	From Structure to Clinic: Discovery of AÂM1 Muscarinic Acetylcholine Receptor Agonist for the Treatment of Memory Loss in Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	0